Bisphosphonates effective in preventing bone complications associated with androgen deprivation therapy
Journal of Supportive Oncology 4(2): 99-100
2006
ISSN/ISBN: 1544-6794 PMID: 16499137 Document Number: 603842
Document emailed within 1 workday
Related Documents
Ziaran, S.; Goncalves, F.M.; Wendl, J.; Trebaticky, B.; Breza, J.S. 2009: Evaluation of bone mass density on patients with prostate cancer prior to the start of androgen deprivation therapy Bratislavske Lekarske Listy 110(9): 559-562Koivisto, P.; Kononen, J.; Palmberg, C.; Tammela, T.; Hyytinen, E.; Isola, J.; Trapman, J.; Cleutjens, K.; Noordzij, A.; Visakorpi, T.; Kallioniemi, O.P. 1997: Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer Cancer Research 57(2): 314-319
Rees, J. 2015: Androgen deprivation therapy and cardiovascular risk Practitioner 259(1785): 5
Buyyounouski, M.K. 2010: Androgen deprivation therapy in high-risk prostate cancer Oncology 24(9): 806; 809
Arai, G.; Okada, H. 2016: Androgen deprivation therapy for prostate cancer: adverse effects and their management Nihon Rinsho. Japanese Journal of Clinical Medicine 74(Suppl 3): 605-609
Soloway, M.S. 1990: The importance of pretreatment testosterone and other prognostic variables in the response to androgen deprivation therapy Progress in Clinical and Biological Research 350: 141-148
Alvarez Rodríguez, S.; Alonso Gordoa, T.; Burgos Revilla, F.Javier. 2018: Current status of androgen deprivation therapy in hormone-sensitive prostate cancer Archivos Espanoles de Urologia 71(3): 247-257
Ying, J.; Yao, D.-H.; Ren, X.-M. 2003: Study of sexual hormone changes in prostate cancer patients before and after androgen deprivation therapy Zhonghua Nan Ke Xue 9(3): 191-192; 196
2015: (P063) Can Some High-Risk Prostate Cancer Patients Be Treated With a Shorter Course of Androgen Deprivation Therapy (ADT)? Oncology 29(4 Suppl. 1)
Pickles, T.; Pollack, A. 2006: The case for dose escalation versus adjuvant androgen deprivation therapy for intermediate risk prostate cancer Canadian Journal of Urology 13(Suppl 2): 68-71
Walsh, M.N. 2000: In an article last summer, you mentioned that a 0.3 milligram daily dose of estrogen is effective in preventing osteoporosis. Is a dose that low also effective for preventing heart disease? Health News 6(3): 10
Ogawa, S. 2010: Bone and Men's Health. Androgen replacement therapy and bone metabolism Clinical Calcium 20(2): 251-257
Rentsch, C.A.; Aebersold, D.M.; Merz, V.; Studer, U.E. 2005: Cancer of the prostate: importance of androgen deprivation and radiotherapy Revue Medicale Suisse 1(19): 1303-1306
Tenner, S.M.; Yadven, M.W.; Kimmel, P.L. 1992: Acute pyelonephritis. Preventing complications through prompt diagnosis and proper therapy Postgraduate Medicine 91(2): 261-268
Neĭmark, A.I.; Muzalevskaia, N.I.; Neĭmark, B.A. 2002: Prospects for preoperative low-intensity laser therapy in preventing postoperative thrombohemorrhagic complications in adenomectomy Urologiia 2002(5): 4-5
Blank, K.R.; Whittington, R.; Arjomandy, B.; Wein, A.J.; Broderick, G.; Staley, J.; Malkowicz, S.B. 1999: Neoadjuvant androgen deprivation prior to transperineal prostate brachytherapy: smaller volumes, less morbidity Cancer Journal From Scientific American 5(6): 370-373
Tiwari, S.; Gupta, S.K.; Mehrotra, M.; Agarwal, G.; Awasthi, P.K.; Godbole, M.M. 2002: Short-term androgen deprivation does not alter CaR and VDR mRNA expression in duodenal mucosa in male rats Indian Journal of Experimental Biology 40(7): 780-784
Shinoda, H. 1995: Inhibitory effects of bisphosphonates on bone resorption Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica 105(5): 285-294
Haibel, H.; Braun, J.; Maksymowych, W.P. 2002: Bisphosphonates--targeting bone in the treatment of spondyloarthritis Clinical and Experimental Rheumatology 20(6 Suppl 28: S162-S166
Fleisch, H. 1987: Experimental basis for the use of bisphosphonates in Paget's disease of bone Clinical Orthopaedics and Related Research 217: 72-78